University Hospitals’ Post

HCA Florida JFK Hospital is pioneering the future of atrial fibrillation (AFib) treatment with a groundbreaking clinical trial utilizing pulsed field ablation technology. This innovative procedure has the potential to revolutionize how electrophysiologists approach the treatment of AFib, ultimately enhancing patient outcomes and quality of life.  AFib is the most common type of heart arrhythmia, affecting close to three million Americans, with that number projected to reach over 12 million in 2030. Treating AFib can significantly improve a patient’s quality of life, lowering their risk of stroke, heart failure, and other cardiovascular complications. Dr. Robert Fishel, Medical Director of Cardiac Electrophysiology at HCA Florida JFK Hospital, performed the procedure and is the lead investigator in the clinical trial.  Acknowledged as one of America’s top 50 hospitals for cardiac surgery by Healthgrades, JFK Hospital stands at the forefront of cardiovascular excellence in the region. To learn more about AFib or to find a physician, visit https://bit.ly/3TMHWeS #HCAFloridaHealthcare #HealthierTomorrows

This past year, we took pride in the fact that two respected thought leaders in interventional cardiology and endovascular interventions delivered speeches at the Leipzig Interventional Course (LINC) on Avinger's Lumivascular technology. LINC is a leading global forum for new methods and technology in the field of vascular medicine held each year in Leipzig, Germany. • Dr. Arne Schwindt, a vascular surgeon at St. Franziskus Hospital in Münster, Germany and a pioneer in the OCT-guided treatment of vascular disease, featured Avinger's Pantheris OCT-guided atherectomy system and the results of the INSIGHT trial in his presentation, "Gender Differences in Treatment of ISR Lesions with the Pantheris Atherectomy Catheter." The INSIGHT trial was designed to evaluate the safety and effectiveness of Avinger's Pantheris image-guided atherectomy system for treating in-stent restenosis (ISR) in lower extremity arteries. • Dr. Michael Lichtenberg, Chief Medical Officer and Director of the Angiology Department and Vascular Center at Klinikum Arnsberg, presented interim data from the post-market IMAGE-BTK trial designed to evaluate the safety and effectiveness of Avinger's Pantheris SV OCT-guided atherectomy system in treating below-the-knee lesions. His presentation was entitled, "Treatment of Stenotic Lesions Below-the-Knee with an OCT-Guided Atherectomy Catheter." #AvingerInnovates #MedicalAdvancements #YearInReview #HealthcareInnovation #PantherisLV #BestOf2023 #YearInRetrospect

With the conclusion of enrollment in JC Medical’s Early Feasibility Study (EFS) evaluating the J-Valve for symptomatic patients at high risk for cardiac surgery with severe aortic regurgitation, I wanted to share a few reflections: 1.     While research in the US can present challenges in the post-COVID environment, the dedication and efforts of the research teams exceeded all expectations. From the study’s National Principal Investigators (PIs) and site PIs to the research nurses to the imagers and hybrid teams, the expertise and commitment to help advance new technologies for patient care were truly commendable. 2.     The commitment of JC Medical’s field team, clinical team members, quality, manufacturing, R&D, operations that made the trial successful in such a short period of time is greatly appreciated and inspiring. Talent is always important, but there are intangibles that become critical in high-pressure situations that cannot be understated. 3.     The FDA’s review branch for heart valve therapies is working hard to ensure public health and are truly committed as an organization to working to help advance new patient technology. 4.     Cardiac Imaging is so critically important as we move to treat new pathologies like the transcatheter treatment for AR. As Cardiac MR becomes a more utilized tool and part of the valvular heart disease guidelines, we will be able to better understand to which patient populations we should direct our therapies. 5.     Patient input into research efforts, as well as their trust, remains integral to the process. 6.     The Cardiovascular field has always been an evidenced-based practice with great interest to move to new heights to improve outcomes. We can be proud that the commitment is very real and continues to be strong. #tavi #fda #AR#J-Valve And....The cake was great!

🚨 New Publication Alert! 🚨 We’re excited to share our latest research on the impact of veno-venous extracorporeal membrane oxygenation (VV-ECMO) on right ventricular (RV) function in ARDS patients. This study provides key insights into the progression of RV dysfunction over time. 📖 Study Title: Assessing Right Ventricle Over Time in Patients on Veno-Venous Extracorporeal Membrane Oxygenation: Insights from Serial Echocardiography 🔬 Background: ARDS often requires VV-ECMO for severe cases, but its effects on RV function are not well-studied. We aimed to fill this gap by examining RV dysfunction in patients undergoing VV-ECMO. 🩺 Methods: Retrospective study at Mayo Clinic with 70 patients. Evaluated RV function using serial echocardiograms post-ECMO. 📊 Key Results: 60.6% had normal RV function at ECMO initiation, dropping to 42% later. RV dysfunction worsened with increased ECMO flow and duration. Moderate RV function decrease linked to ECMO flow (OR = 2.32) and duration (OR = 1.01). 🔍 Discussion: Our findings emphasize the need for regular RV monitoring during VV-ECMO therapy to improve outcomes. 💡 Clinical Implications: Frequent RV assessments should be integrated into clinical practice to aid risk stratification and personalized care. 📖 Read the Full Study: https://lnkd.in/eXVMsgyk We hope this research enhances ARDS patient management and understanding of VV-ECMO’s impact on cardiac function. Shahin Isha, MD, Sai Abhishek Narra, Pablo Moreno Franco, MD, Pramod Guru. MD,DM,FASN, Sanjay Chaudhary, Devang Sanghavi, MD, MHA, FCCP, Si Pham, Maher Baz, Govind Panda, Nathan Waldron, Kyle Bohman, Rohan Goswami #MedicalResearch #CriticalCare #Cardiology #ARDS #VVECMO #Healthcare #Echocardiography

💪Our team traditionally takes part in the scientific and practical conference "III Vinnytsia Course of Cardiac Intervention, Imaging and Stimulation", which takes place on 23-24 February 2024 in Vinnytsia ➡ The event is dedicated to the 50th anniversary of the Resuscitation and Intensive Care Unit of the Cardiology Department for patients with myocardial infarction.  🖌We are glad and fully support cardiologists, interventional cardiologists, cardiac surgeons, physicians, family doctors in their desire to expand their knowledge of the latest achievements of interventional cardiology, as well as learn modern approaches to the treatment of patients with heart and vascular diseases #interventionalcardiologists #cardiac #surgeons #stent Andrii Usenko

Join Medics4RareDiseases and FOP Friends for a unique evening reception, at the prestigious Hunterian Museum, at the Royal College of Surgeons of England on 13th February 2024. 'First, Do No Harm: Expert Reflections on a Rare Bone Disease' is an opportunity to learn about how patients and families contribute to a greater understanding of rare disease through the story on one rare bone condition, Fibrodysplasia Ossificans Progressiva. Clinicians, patients and advocates will share stories about the lived experience of people with FOP from the 18th century to the present day. Attendees will also be able to visit the Hunterian Museum and the skeleton of a man who lived with this condition in the 1700s. FOP is an example of a rare genetic condition that has been familiar to medicine for hundreds of years, but is not familiar to the average healthcare professional. It is characterised by the abnormal development of bone in skeletal muscles and connective tissues, progressively locking joints in place and limiting movement. However without healthcare professional awareness of FOP the basic tenet of medicine, ‘First, do no harm’, is easily missed. When living with FOP any trauma, including surgery, can trigger a flare response resulting in abnormal bone growth in the affected area. You will hear from clinicians and advocates who have been pivotal in working towards treatment and improving the lives of those living with this rare condition. They will also serve as a reminder about the principles of clinical care that can make all the difference to those living with rare diseases. 💬 Talks from advocates and clinicians 🎟 Visit the Hunterian Museum and RCSEng Anatomy and Pathology Museum, skeletons of two people who lived with FOP, two centuries apart, one in the mid 1700s the other at the end of the 20th century. 🥂 Drinks and canapés 🔗 Networking reception Reserve your place here https://lnkd.in/eCVr_2iZ The Royal College of Surgeons of England #RareDisease #RareDiseaseDay #RareDiseaseDay24 #surgicaleducation #museum #genetics #PatientAdvocacy #Research #History

Join Concept Medical at Cardiovascular Research Technologies (CRT) educational forum to get a glimpse of Novel US FDA Breakthrough designated Technologies that are altering standards of care and transforming treatment of complex cardiovascular procedures for physicians and health systems Worldwide

https://lnkd.in/gjher2hJ Article title: The Journey of TAVR Author(s): Luis M de la Fuente*; Facundo E Peñaloza Journal: Journal of Cardiovascular Medicine and Cardiology Journal ISSN: 2455-2976 Abstract: Eighteen years ago, Alain Cribier, MD, and colleagues performed the first transcatheter aortic valve replacement in the year 2002 at Charles Nicolle University Hospital, University of Rouen, France [1]. In the intervening years, Transcatheter Aortic Valve Replacement (TAVR) has completely revolutionize the landscape of Cardiovascular medicine and brought a new spotlight in a treatment previously reign by Surgeons. TAVR was born at the beginning with a mission to answer an unmet need. Before the development of transcatheter prosthesis, options were limited for many patients with severe aortic stenosis. #CoronaryArteryDiseases #ValvularHeartDisease #Electrophysiology #CardiacElectrophysiology #Echocardiography #InterventionalCardiology #ClinicalCardiology #NuclearCardiology #AcuteCoronarySyndromes #ArrhythmiaEP #CVImaging #CVDPrevention #CardiacArrhythmias #Peertechz #PeertechzPublications #OpenAccess #ScientificJournals #PeerReviewedJournals #OpenAccessPublishers #CardiacPhysiology #CardiacRegeneration #CardiacRehabilitation #Cardiomyopathies #CardiovascularDrugs #CardiovascularTherapy #CardiovascularAnatomy #CongenitalHeartDefects 

Excellent results of the 93 patient study of the AMDS Stent showing massive reduction in All Cause Mortality and improvements in many other outcomes for patients with Acute DeBakey Type I Aortic Dissection. Harbright Ventures and our network of investors is proud to have supported this game-changing technology that will save many lives. Looking forward to the #PMA from the FDA soon! Dr. Wilson Y. Szeto said, "Acute DeBakey Type I (ADTI) dissections remain one of the most life-threatening emergencies that cardiac surgeons address. Despite the seriousness of the condition, there have been limited surgical advancements in the last several decades, demonstrating an unequivocal need for innovation to better treat these patients. I am extremely encouraged by the results of the PERSEVERE study which indicate that AMDS significantly reduces 30-day MAE's in ADTI patients complicated by malperfusion and helps prevent DANE. The ease of use and approachability of the AMDS device will expand the ability of cardiac surgeons to offer a more comprehensive treatment for these patients amidst a life-threatening emergency." https://lnkd.in/e5Veu9TF #AMDS #Artivion #MedicalDeviceInnovation #savinglives #venturecapital $AORT

📢 Original Research-Vol. 25 No. 3 💕 Title: Impact of Classical Risk Factors on Subclinical Carotid Atherosclerosis Progression: Insights from a Non-Diabetic Cohort 🤵 Authors: Eva Szabóová*, Alexandra Lisovszki, Peter Kolarcik, Eliška Fatĺová, Tomáš Molnár, Martin Bujdoš, Peter Szabó 🔔 Full Text: https://lnkd.in/ga36e3Ea 🔑 Keywords: subclinical atherosclerosis; atherosclerotic plaque; intima-media thickness; cardiovascular risk factors; risk score 😎Welcome to your reading! #Cardiovascular #HeartHealth #CVD #HeartDisease #HealthyHeart #HeartCare #HeartAwareness #StrokePrevention #HeartAttack #Cardiology #HeartFailure #HeartResearch #BloodPressure #Cholesterol #Atherosclerosis #HeartRisk #HeartAwarenessMonth #HeartMonth #PreventHeartDisease #HealthyLifestyle #PediatricCardiology #CardiacHealth #RareDisease #CardiacTumors #MedicalResearch #HealthcareAwareness #HeartHealth #PediatricHealth #Cardiology #HeartDisease #TumorResearch #MedicalScience #CardiovascularHealth